Inside the triple helix: technology transfer and commercialization in the life sciences.

The transfer and subsequent application of academic research results has demonstrable benefits for health care, researchers, universities, companies, and local economies. Nonetheless, at least three general concerns exist: bias in the reporting of results, limited revenues from these activities, and the lack of data to evaluate technology transfer activities. Future efforts with regard to technology transfer in the life sciences will need to recognize its importance without ignoring concerns or overestimating benefits. Next steps include better monitoring of university-industry relationships, the development of a better data system, the dissemination of best practices in technology transfer management, and evaluation of national technology-transfer policies.

[1]  Kimberly S. Hamilton,et al.  The increasing linkage between U.S. technology and public science , 1997 .

[2]  J. Streim,et al.  America's other drug problem. , 1994, Provider.

[3]  M. Mcclellan,et al.  Is technological change in medicine worth it? , 2001, Health affairs.

[4]  Henry Etzkowitz,et al.  The Making of an Entrepreneurial University: The Traffic Among MIT, Industry, and the Military, 1860–1960 , 1988 .

[5]  Edwin Mansfield,et al.  Academic research and industrial innovation , 1991 .

[6]  Irwin Feller.  Technology Transfer from Universities , 1996 .

[7]  M. Friedberg,et al.  Evaluation of conflict of interest in economic analyses of new drugs used in oncology. , 1999, JAMA.

[8]  H. Etzkowitz,et al.  Profiting from knowledge: Organisational innovations and the evolution of academic norms , 1991 .

[9]  J. Newhouse,et al.  An iconoclastic view of health cost containment. , 1993, Health affairs.

[10]  R. Eisenberg,et al.  Bayh-Dole Reform and the Progress of Biomedicine , 2002, American Scientist.

[11]  Frederick H. Buttel,et al.  University-Business Partnerships: An Assessment. , 1997 .

[12]  D Blumenthal,et al.  Participation of life-science faculty in research relationships with industry. , 1996, The New England journal of medicine.

[13]  D Blumenthal,et al.  Relationships between academic institutions and industry in the life sciences--an industry survey. , 1996, The New England journal of medicine.

[14]  S. Schroeder,et al.  Academic medicine as a public trust. , 1989, JAMA.

[15]  C. Gross,et al.  Scope and impact of financial conflicts of interest in biomedical research: a systematic review. , 2003, JAMA.

[16]  Gerard F Anderson,et al.  Cross-national comparisons of health systems using OECD data, 1999. , 2002, Health affairs.

[17]  L. Kohn,et al.  To Err Is Human : Building a Safer Health System , 2007 .

[18]  L. Opie.  Conflict of interest in the debate over calcium-channel antagonists. , 1998, The New England journal of medicine.

[19]  V. Fuchs,et al.  Physicians' views of the relative importance of thirty medical innovations. , 2001, Health affairs.

[20]  David Zilberman,et al.  University Research and Offices of Technology Transfer , 2002 .

[21]  N. Dorfman,et al.  Route 128 : The Development of a Regional High Technology Economy : Research Policy , 1983 .